Onco Actu du 26 avril 2018

	2. Etiologie
Belief in fake causes of cancer is rife [Cancer Research UK] “There is no guarantee against getting cancer but by knowing the biggest risk factors we can stack the odds in our favour to help reduce our individual risk of the disease, rather than wasting time worrying about fake news.”
Fake cancer causes belief 'rife', research suggests [BBC News] One-third incorrectly believed that electromagnetic frequencies (35%) and eating genetically modified (GM) food (34%) were risk factors, while 19% thought microwave ovens and 15% said drinking from plastic bottles caused cancer, despite a lack of good scientific evidence.
	3.1 Prévention - Tabac
There’s No Smoking in Disney Films. What About When It Owns Fox? [NY Times] Activists are continuously pressuring studios over one cause or another, but Mr. Murdoch has frequently dismissed such efforts as political correctness run amok. Disney, on the other hand, pays extraordinary attention to its brand perception, which activists often try to use to their advantage.
	3.1.1 Prévention - Tabac - e-cigs
Should we recommend e-cigarettes to help smokers quit? [BMJ] Smokers want to vape, it can help them quit, and it’s less harmful than smoking, say Paul Aveyard and Deborah Arnott. But Kenneth C Johnson argues that smokers who vape are generally less likely to quit and is concerned about youth vaping as a gateway to smoking, dual use, and potential harms from long term use.
	3.4 Chimioprévention
Women with breast cancer risk opting out of tamoxifen therapy [PharmaTimes] The research team, based at the University of Leeds, Northwestern University, University College London and Queen Mary University of London, found women with children were more likely to take up the offer of tamoxifen, and that social class, educational attainment and ethnicity had no effect on uptake.
	3.8 Prévention - Alimentation
The Case Against: Nutrition Science is Not Up to the Task [BMJ] While public health emergencies such as the current “diabesity” epidemics compel experts to enact some, if imperfect, advice now, the risk of unintended consequences remain. Enacting prevention guidelines based on lesser evidence risks repeating what might be a tragic history of doing more harm than good.
	4.12 Biopsies liquides
Demystifying Liquid Biopsies [ASH] These so-called “liquid biopsies” can allow clinicians to detect tumors early and non-invasively track tumor changes in real time. Non-invasive ctDNA tests are still years away from routine clinical use, though.
	4.2 Dép., diag. & prono. - Génome
Large National Sequencing Projects in Europe [ESMO] Two editorial articles published in April 2018 issue of the Annals of Oncology underpin emergence of modernised genomics services in France and UK with explanation of sequencing and informatics infrastructure, a process of local transformation, and expansion in skills and new professional networks that have evolved through delivery of the projects.
	5. Traitements
Vitamin C as a treatment for cancer: the evidence so far [Cancer Research UK] Either way, given the mixed results so far, media reports around vitamin C could be doing more harm than good. And as for vitamin C as the next big wonder drug? The signs aren’t pointing that way just yet.
	5.10 Traitements - Essais
Number needed to treat – one way to frame harms vs. benefits: An update to our toolkit [HealthNewsReview] It provides another way to frame the impact of a treatment; more specifically, it tells us how many people need to receive a medication or intervention for just one person to benefit (or to avoid one adverse outcome).
Cancer centers sell out science when they advertise clinical trials as treatment [STAT] Suggesting that trials give patients “an edge” obscures the fact that most new drugs turn out not to be superior to standard care and, in some cases, are unacceptably toxic. In addition, trials often entail more frequent visits and potentially burdensome research procedures like organ biopsies.
	5.12.10 Immunothérapies - Fusions et acquisitions
Juno CEO and Co-founder steps down in wake of Celgene acquisition |Pharmafile] Neither Bioshop nor Celgene have made any formal announcement on the departure.
	5.12.6 Immunothérapies - AMM
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma [BMS] First and only PD-1 inhibitor approved in the EU to offer every four-week dosing.
	5.2 Pharma
After mega-round investment, ADC Therapeutics cans PhI trial in HER2 [EndPoints] The 502 drug was being tested in a Phase I trial with patients who have HER2-positive cancers. But as the company’s CMO Jay Feingold explains it, the HER-2 targeted ADC wasn’t working well enough in low doses, which is a problem considering the side effects.
	5.5 ASCO
New, High-Impact Studies to Be Featured at World’s Largest Clinical Cancer Research Meeting [ASCO] The theme of this year’s conference is Delivering Discoveries: Expanding the Reach of Precision Medicine. More than 2,500 abstracts were accepted for presentation on site at the Annual Meeting, and an additional 3,350 abstracts were accepted for online publication.
	5.5.1.1 ASCO (général) - Industriels
Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting [Genmab] Genmab A/S announced today that nine industry sponsored daratumumab abstracts, one industry sponsored ofatumumab abstract and one tisotumab vedotin abstract have been accepted for presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1-5.
	6. Lutte contre les cancers
A Lifesaving Pump for Cancer Patients Is Being Phased Out [NY Times] The devices, called Codman pumps, are made by Cerenovus, a subsidiary of Johnson & Johnson, which told doctors in a letter dated April 4 that it had decided to stop production effective April 1 “because of significant and multiple raw material supply constraints within the manufacturing process.”
	6.1 Observation
Most lung and bowel cancers being diagnosed too late, data shows [The Guardian] Most Australians with lung and bowel cancers are being diagnosed too late, data released by Cancer Australia shows, prompting renewed calls for governments to make developing early detection tests a priority.
	6.10 Politiques
France’s science minister says she’s putting research at the centre of Macron’s government [Nature] We also want to boost France’s performance in Horizon 2020. The success rate of France’s applications for Horizon 2020 grants is the second-highest of member states, but we have the potential to do better.
	6.7.1 IA/bioinformatique
With €1.5 billion for artificial intelligence research, Europe pins hopes on ethics [Science] On 24 April, a group of nine prominent AI researchers, including Schölkopf, took matters into their own hands and offered suggestions in an open letter. They urge governments to set up an intergovernmental European Lab for Learning and Intelligent Systems (ELLIS), inspired by the European Molecular Biology Laboratory.
	6.7.2 Applis
Collaborating with patients to provide online access to health records [BMJ] Selina Brudnicki and Sandra Dalziel discuss the experience and lessons learnt in jointly developing a new secure patient portal.